key: cord-0840127-icqcpn0u
authors: Vigliar, Elena; Pisapia, Pasquale; Dello Iacovo, Filippo; Alcaraz‐Mateos, Eduardo; Alì, Greta; Ali, Syed Z.; Baloch, Zubair W.; Bellevicine, Claudio; Bongiovanni, Massimo; Botsun, Pavlina; Bruzzese, Dario; Bubendorf, Lukas; Büttner, Reinhard; Canberk, Sule; Capitanio, Arrigo; Casadio, Chiara; Cazacu, Eugeniu; Cochand‐Priollet, Beatrix; D’Amuri, Alessandro; Davis, Katelynn; Eloy, Catarina; Engels, Marianne; Fadda, Guido; Fontanini, Gabriella; Fulciniti, Franco; Hofman, Paul; Iaccarino, Antonino; Ieni, Antonio; Jiang, Xiaoyin Sara; Kakudo, Kennichi; Kern, Izidor; Kholova, Ivana; Linton McDermott, Kathryn M.; Liu, Chinhua; Lobo, Anandi; Lozano, Maria D.; Malapelle, Umberto; Maleki, Zahra; Michelow, Pamela; Mikula, Michael W.; Musayev, Jamal; Özgün, Gonca; Oznur, Meltem; Peiró Marqués, Francisca Maria; Poller, David; Pyzlak, Michal; Robinson, Betsy; Rossi, Esther Diana; Roy‐Chowdhuri, Sinchita; Saieg, Mauro; Savic Prince, Spasenija; Schmitt, Fernando C.; Seguí Iváñez, Francisco Javier; Štoos‐Veić, Tajana; Sulaieva, Oksana; Sweeney, Brenda J.; Tuccari, Giovanni; van Velthuysen, Marie‐Louise; VanderLaan, Paul A.; Vielh, Philippe; Viola, Patrizia; Voorham, Quirinus J. M.; Weynand, Birgit; Zeppa, Pio; Faquin, William C.; Pitman, Martha Bishop; Troncone, Giancarlo
title: COVID‐19 pandemic impact on cytopathology practice in the post‐lockdown period: An international, multicenter study
date: 2022-01-10
journal: Cancer Cytopathol
DOI: 10.1002/cncy.22547
sha: 8f91fdd14e4743f96781ee13dbd88b06c89ea7a2
doc_id: 840127
cord_uid: icqcpn0u

BACKGROUND: In a previous worldwide survey, the authors showed a drastic reduction in the number of cytological specimens processed during the coronavirus disease 2019 “lockdown” period along with an increase in malignancy rates. To assess the continued impact of the pandemic on cytological practices around the world, they undertook a second follow‐up worldwide survey collecting data from the post‐lockdown period (2020). METHODS: Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post‐lockdown period (2020), which ranged from April 4 to October 31. Differences between the post‐lockdown period and the corresponding 2019 period were evaluated, and the authors specifically focused on rates of malignant diagnoses. RESULTS: A total of 29 respondents from 17 countries worldwide joined the survey. Overall, a lower number of cytological specimens (n = 236,352) were processed in comparison with the same period in 2019 (n = 321,466) for a relative reduction of 26.5%. The overall malignancy rate showed a statistically significant increase (12,442 [5.26%] vs 12,882 [4.01%]; P < .001) during the same time period. Similar results were obtained if both malignancy and suspicious for malignancy rates were considered together (15,759 [6.58%] vs 16,011 [4.98%]; P < .001). CONCLUSIONS: The data showed a persistent reduction in the cytological specimen volume during the post‐lockdown period (2020). However, the relative increase in the cytological workload in the late part of the post‐lockdown is a promising finding of a slow return to normality.

The end of 2019 was characterized by the rise of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2. [1] [2] [3] The pandemic status was officially declared by the World Health Organization on March 11, 2020. 4 At the time of this writing (July 2021), more than 185 million people had been reported to be test-positive, with more than 4 million deaths worldwide. 5 The COVID-19 pandemic has significantly affected medical and laboratory practices around the world, including cytopathology practices. [6] [7] [8] [9] In fact, to "flatten the curve," governments worldwide have imposed severe countermeasures limiting freedom of movement and everyday activities to reduce the spread of the disease. A major consequence of these limitations is the postponement of "nonurgent" medical and elective surgical procedures, which has resulted in a significant reduction in the activity of cytopathology services. [8] [9] [10] [11] [12] For example, in our previous survey of 41 laboratories from 23 different countries, there was a drastic reduction in the number of cytological specimens processed during the "lockdown" period along with a higher malignancy rate in comparison with the pre-lockdown period because of the prioritization of cytological specimens from individuals with a high cancer risk. 8 The post-lockdown period in the second part of 2020 saw less restrictive measures. All medical services, including cytopathology, increased their services but still experienced a reduction in cytological specimens with respect to the corresponding prepandemic period and continued to see a persistently higher malignancy rate. 13, 14 However, these data reflect only a single institution's experience, and global data regarding cytological practices in the post-lockdown period are limited. To fill this knowledge gap, a worldwide survey was taken to investigate the state of cytopathology laboratories during the COVID-19 pandemic post-lockdown period (2020).

In this study, we applied the same methodology followed in our previous survey. 8 Briefly, an Excel questionnaire template was sent via email to the cytopathologists who had participated in the previous survey; these included the CytoESP Working Group (cytopathologists from the European Society of Pathology; https://www.esp-patho logy. org/worki ng-group s/esp-worki ng-group s/cytop athol ogy. html) and the cytopathologists who had participated in at least 1 of the 9 Annual National Molecular Cytopathology meetings in Naples, Italy (https://www.molec ularc ytopa tholo gy.com/), regardless of the single-participant sample workload. Only a single invitation email with no subsequent reminders was sent. Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post-lockdown period and to stratify the data by consecutive 3-week intervals. The study period was individualized for each institution because of the variability of lockdowns among countries. In countries in which a lockdown did not take place, cytopathologists were asked to provide data from the first 12 weeks after the peak infection spread. Only data obtained from laboratories that had participated in both surveys were compared with those reported in the corresponding baseline period in 2019. Questions included in the survey are listed in Figure 1 . All information regarding human material was managed with anonymous numerical codes, and all samples were handled in compliance with the Declaration of Helsinki. The data were grouped into four 3-week periods, as previously reported. 13 Briefly, the overall workload rates for each specimen type were compared, and the total number of processed samples was recorded. Moreover, as far as the distribution of diagnostic classes was concerned, the numbers of suspicious and malignant nongynecological diagnoses were compiled.

Differences between the post-lockdown period (2020) and the corresponding 2019 period were evaluated on the basis of absolute numbers. Differences in the rates of malignant diagnoses were assessed via the χ 2 test; P values lower than .05 were deemed to be statistically significant. joined the survey. For the most part, the data reflected single-institution activity except in 1 instance in which multi-institutional data were provided (Pathological National Automated Archive Public Pathology Database of the Netherlands; https://www.palga.nl/en/publi cdatab ase.html). Because the timing of COVID-19 lockdowns differed among countries, each institution selected its most representative first 12 weeks of post-lockdown practice between April 4 and October 31, 2020.

Overall, a lower number of cytological specimens (n = 236,352) were processed during the post-lockdown period (2020) with respect to the same period in 2019 (n = 321,466) for a reduction of 26.5% ( Table 1 ). The reduction was significant in each of the consecutive 3-week periods (period I, 49,724 vs 82,720; -39.9%; period II, 60,882 vs 88,744; -31.4%; period III, 60,715 vs 77,917; -22.1%; period IV, 65,031 vs 72,085; -9.8%; Table 2 ), although there was a trend toward a return to baseline volumes. Overall, the greatest reductions in the number of processed samples were observed for thyroid (-32.8%), cervical-vaginal tract (-30.7%), breast (-20.8%), serous cavity (-16.8%), salivary gland (-14.4%), respiratory tract (-12.2%), urine (-10.5%), and lymph node specimens (-7.5%); only 4 sample categories (central nervous system, gastrointestinal tract, biliary tract, and bone marrow specimens) showed an increase in the number of processed cytological samples ( Table 3) .

The overall malignancy rate of all samples obtained during the study period showed a statistically significant (Table 4) . Notably, the highest values were observed in period I (Table 4 ).

To the best of our knowledge, this is the first international, multicenter study to evaluate the cytopathological laboratory practices around the world during the immediate post-lockdown period. Notably, an overall reduction of processed cytological samples (26.5%) was observed between the post-lockdown period in 2020 and the corresponding period in 2019, with differences ranging from -72.6% to +30.6%. The absolute reduction in the number of processed specimens is alarming because of the increased risk for delayed treatment of patients with cancer. Only 4 specimen categories (central nervous system, gastrointestinal tract, biliary tract, and bone marrow specimens) did not show a decrease in the number of processed cytological samples in comparison with the prepandemic baseline. Overall, the highest reduction in samples was reported during the first 6 weeks in the post-lockdown period The data are grouped into four 3-week periods.

(period I, -39.9%; period II, -31.4%) in comparison with the other 6 examined weeks (period III, -22.1%; period IV, -9.8; Table 2 ). Interestingly, other than different values of the overall reduction in cytology volume from each body site, different trends were observed in cytology practice recovery (Fig. 2) . For example, Papanicolaou smears and thyroid samples showed a slow return to pre-COVID-19 levels; a possible explanation for the persistent reduction in the number of processed samples, particularly during the first 6 weeks of the post-lockdown period, may be the gradual reactivation of screening programs. Conversely, samples at high oncological risk, such as lymph node, breast, and respiratory tract fine-needle aspirates and serous fluids, showed a faster tendency to recover to pre-COVID-19 practice levels, as evident in the immediate post-lockdown period (period I or II); moreover, a steady trend during the subsequent periods was observed. This phenomenon probably reflected the attitudes of clinicians and cytopathologists for prioritizing specific specimen types. A fluctuating trend, with only a slight reduction in comparison with the pre-COVID-19 era (2019), was finally observed for sites such as the soft tissue, central nervous system, liver, pancreas, and gastrointestinal and biliary tract; however, the low volumes analyzed probably do not enable distinctive kinetics to be demonstrated. Overall, for the majority of sample types, there seemed to be quite significant variation from the lockdown time period to period I and the post-lockdown period (2020; Fig. 2 and Tables 2 and 3) . As for the malignancy rate and the malignant and suspicious rate during the COVID-19 post-lockdown period, a higher value in all examined periods was observed in comparison with the corresponding period in 2019 (Table 4) . Notably, the highest values were observed in period I (Table 4) . Despite the interesting results, several limitations affect our article. First of all, the number of participants was limited with respect to the previous survey. Second, more than half of the examined cases belonged to a single institution (laboratory #17). However, even without this laboratory, an overall reduction of 20.8% (88,990 vs 112,398) was observed. Similarly, there was a statistically significant increase (5.9% vs 5.1%; P < .001) in the overall malignancy rate and in the overall malignant and suspicious for malignancy sample rates when they were considered together (8.8% vs 7.2%; P < .001) in comparison with the corresponding period in 2019.

In conclusion, the COVID-19 pandemic era was characterized by decreases and delays in identifying new cancers. [15] [16] [17] Data generated from the present international, multicenter study showed that the postponement of "nonurgent" medical procedures was still observed during the post-lockdown period. Nonetheless, the policy of prioritizing high-risk patients has proven to be effective and should be pursued in the future, if necessary. In fact, when we consider the overall data, there was a significant increase in the malignancy rate between 2019 and 2020 when only malignant cases or when both malignant and suspicious for malignancy diagnoses were considered. These data strongly support the role of cytology in the diagnostic management of high-risk patients with cancer, even during this unprecedented health care emergency. 18, 19 However, despite these results, the continued reduction of processed cytological samples in the post-lockdown period, which is related to national health care system countermeasures and the persistent reluctance of patients to go to the hospital, represents a global health care issue and serves as an important reminder of the potential consequences that such national policy measures can have on individuals with cancer. 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges

China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

A novel coronavirus outbreak of global health concern

World Health Organization

Managing COVID-19 in the oncology clinic and avoiding the distraction effect

Coronavirus lockdown: what I learnt when I shut my cancer lab in 48 hours

Global impact of the COVID-19 pandemic on cytopathology practice: results from an international survey of laboratories in 23 countries

Impact of the COVID-19 pandemic on cytology practice: an international survey in the Asia-Pacific region

Impact of ongoing COVID-19 pandemic on cytology: an institutional experience

The impact of the COVID-19 pandemic and the associated Belgian governmental measures on cancer screening, surgical pathology and cytopathology

Cytology in the time of coronavirus disease (COVID-19): an Italian perspective

Cytopathology practice during the COVID-19 postlockdown: an Italian experience

Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic

Declines in cancer screening during COVID-19 pandemic

Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors

Cancer screening in the coronavirus pandemic era: adjusting to a new situation

The two sides of cytopathology during the COVID-19 health emergency: screening versus diagnosis

Delay in cancer screening and diagnosis during the COVID-19 pandemic: what is the cost?

Thermo Fisher Scientific outside the submitted work. Paul A. VanderLaan reports personal fees from Gala Therapeutics, Intuitive Surgical, and Galvanize Therapeutics outside the submitted work. Giancarlo Troncone reports personal fees from Roche, MSD, Pfizer, Boehringer Ingelheim, Eli Lilly, BMS, GSK, Menarini, AstraZeneca, Amgen, and Bayer outside the submitted work. The other authors made no disclosures. 

Elena Vigliar reports personal fees from Diaceutics and AstraZeneca outside the submitted work. Lukas Bubendorf reports personal fees from Janssen, Takeda, AstraZeneca, Bayer, and Boehringer Ingelheim, from Systems Oncology; and grants from Sanofi outside the submitted work. Reinhard Büttner reports belonging to advisory boards for and receiving lecture fees from BMS, MSD, Novartis, Roche, Lilly, AstraZeneca, Lumina, AbbVie, Amgen, Boehringer Ingelheim, Merck-Serono, Qiagen, and Pfizer outside the submitted work. Xiaoyin Sara Jiang reports having been a consultant for Leica and having belonged to an advisory panel for Roche. Umberto Malapelle reports personal fees from Diaceutics, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, GSK, and Merck outside the submitted work. Spasenija Savic Prince reports personal fees from MSD, AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, and